Tag: PER TRI

Nuvalent Highlights Pipeline and Business Achievements, Reiterates Key Anticipated Milestones, and Reports Second Quarter 2025 Financial Results

Initiated rolling NDA submission for zidesamtinib for TKI pre-treated patients with advanced ROS1-positive NSCLC, with target completion in the third quarter of 2025 Initiated ALKAZAR...

- A word from our sponsors -

Newsletter Signup

Name(Required)

First Last

Email(Required)

Enter Email Confirm Email

CAPTCHA

Privacy(Required)

I agree with the storage and handling of my data by this website. - Privacy Policy *

Comments

This field is for validation purposes and should be left unchanged.

HomeTagsPER TRI

Etoiles Capital Group Co., Ltd Announces Pricing of US$5.6 million Initial Public Offering

Orezone to Commence Trading on the ASX Under Ticker “ORE”

Bluejay Diagnostics Provides Second Quarter Business and Corporate Update

Tag: PER TRI

Nuvalent Highlights Pipeline and Business Achievements, Reiterates Key Anticipated Milestones, and Reports Second Quarter 2025 Financial Results

Newsletter Signup

Explore

Press Releases

News & Opinion

Living

Others

Follow us